



**“Working together –  
theory and practice”**

**1**

**28 June 2009  
Amsterdam  
The Netherlands**



# PRE-CONGRESS COURSE 1

*Organised by the Paramedical Group*

## Table of contents

<b>Program overview</b>	<b>Page 2</b>
<b>Sponsor list</b>	<b>Page 4</b>
<b>Speakers' contributions</b>	
The role of the nurse in The Netherlands - <b><i>Karin Feicke (The Netherlands)</i></b>	<b>Page 5</b>
The impact of the metabolic fitness on physically inactive obese women with a body mass index (BMI) over 30 and polycystic ovary syndrome (PCOS) - <b><i>Birgitte Raaschou (Denmark)</i></b>	<b>Page 16</b>
Ultrasound - how it works - <b><i>Ellen van de Vorst (The Netherlands)</i></b>	<b>Page 28</b>
Patient education and involvement using the internet – <b><i>Wouter Tuil (The Netherlands)</i></b>	<b>Page 37</b>
Vitrification of human embryos: Will it replace slow controlled-rate freezing? - <b><i>Maureen Wood (United Kingdom)</i></b>	<b>Page 45</b>
Vitrification workshop - <b><i>G. Bocken (Belgium)</i></b> and <b><i>I. De Croo (Belgium)</i></b>	<b>Page 62</b>
<b>Notes</b>	<b>Page 76</b>

# PRE-CONGRESS COURSE 1 - PROGRAM

## Working together - theory and practice

*Organised by the Paramedical Group*

**Course co-ordinators:** Heidi Van Ranst (Belgium) and Heidi Birch (United Kingdom)

**Course description:** This course is particularly suitable for laboratory, nursing and related staff who wish to have the opportunity to work together. By the end of the day the delegates will have an understanding of how colleagues work which will enhance working relationships and benefit patient care.

**Target audience:** Nurses, counsellors and affiliated paramedics

Chairman: Heidi Van Ranst (Belgium)

- 09:00 - 09:10 Introduction - **Heidi Van Ranst (Belgium)**
- 09:10 - 09:30 The role of the nurse in The Netherlands - **Karin Feicke (The Netherlands)**
- 09:30 - 10:00 The impact of the metabolic fitness on physically inactive obese women with a body mass index (BMI) over 30 and polycystic ovary syndrome (PCOS) - **Birgitte Raaschou (Denmark)**
- 10:00 - 10:30 Ultrasound - how it works - **Ellen van de Vorst (The Netherlands)**
- 10:30 - 11:00 Coffee break**
- 11:00 - 11:45 Patient education and involvement using the internet - **Wouter Tuil (The Netherlands)**
- 11:45 - 12:30 Vitrification of human embryos: Will it replace slow controlled-rate freezing? - **Maureen Wood (United Kingdom)**
- 12:30 - 13:30 Lunch**

### **Afternoon workshops**

**Group 1:** Vitrification

*Chair:* Heidi Van Ranst (Belgium) & Anneleen Van de Velde (Belgium)

*Speakers:* **G. Bocken (Belgium)** and **I. De Croo (Belgium)**

Practical demonstrations on vitrification

**Group 2:** Ultrasound

*Chair: Jolienke Schoonenberg-Pomper (The Netherlands) & Liz Corrigan (United Kingdom)*

Speaker: **E. Van de Vorst (The Netherlands)**

Simple physics, basic training and trouble shooting

**Group 3:** Patient education and involvement using the internet

*Chair: Jolienke Schoonenberg-Pomper (The Netherlands) & Liz Corrigan (United Kingdom)*

Speaker: **W. Tuil (The Netherlands)**

Going on a tour in a virtual hospital

**Amsterdam 2009**

**Syllabus Paramedical pre-congress course**

## **Sponsors**

### ***Air Liquide***

Contact: Filip Vydts  
[Filip.Vydts@AirLiquide.com](mailto:Filip.Vydts@AirLiquide.com)



### ***BK Medical***

Contact: Lisbeth Gorr  
[hg@bkmed.dk](mailto:hg@bkmed.dk)




### ***COOK medical***

Contact: Ann Dellaert  
[Ann.Dellaert@cook.be](mailto:Ann.Dellaert@cook.be)



### ***Cryobios***

Contact: Béatrice Ledos  
[bl@cryobiosystem-imv.com](mailto:bl@cryobiosystem-imv.com)



### ***Hazgo***

Contact: Uri Lauwers  
[uri.lauwers@hazgobelgium.com](mailto:uri.lauwers@hazgobelgium.com)



### ***Eppendorf***

Contact: Ines Hartmann  
[hartmanI@Eppendorf.DE](mailto:hartmanI@Eppendorf.DE)



### ***Irvine Scientific***

Contact: Fairy Zare  
[fzare@irvinesci.com](mailto:fzare@irvinesci.com)



### ***K-systems***

Contact: Louise Frøstrup  
[lf@k-systems.dk](mailto:lf@k-systems.dk)



### ***Nikon***

Contact: Amber Boekel  
[amber.boekel@nikonbv.nl](mailto:amber.boekel@nikonbv.nl)



# The role of the nurse in the Netherlands

Karin Feicke MANP  
Fertility clinic  
University Medical Center Groningen  
The Netherlands

ESHRE Amsterdam 28th June 2009



---

---

---

---

---

---

---

---

## Learning objectives

- Dutch facts and numbers
- Nursing and health care teams in NL
- Changes in the health care system
- Example: UMCG Fertility Clinic
  - Nurses tasks and interventions
  - Focus: Health education
  - Focus: Care for emotional well being
- Challenges for nurses

Karin Feicke MANP



---

---

---

---

---

---

---

---

## Dutch facts and numbers

Total population	16.5 million
Age at birth from first child	29.4 years
Number of children per woman	1.7
IVF clinics with laboratory	13
IVF treatments	15000
IVF treatments reimbursed	3
IVF children	1:40
Nurses in reproductive health care	200

J.A.M. Kremer et al 2005 · M. Spell, Eshre Barcelona 2008  
[www.cbs.org](http://www.cbs.org) · [www.who.org](http://www.who.org)

Karin Feicke MANP



---

---

---

---

---

---

---

---

## Nursing and health care teams in the Netherlands



---

---

---

---

---

---

---

---

## Training and regulations for nurses

Ministry of Education, Culture and Science

Secondary professional education



2nd level nurse

Higher professional education (bachelor)



1st level nurse

Post HBO - MANP



Nurse practitioner

Karin Feicke MANP



---

---

---

---

---

---

---

---

## Levels of nurses

First level nurse (HBO) is a higher level nurse

- Assesses the whole situation and decides the appropriate level of nursing care
- Directs second level nurses (MBO)

National training programme for fertility nurses since 2007

Karin Feicke MANP



---

---

---

---

---

---

---

---



## Nurses and the law

### Individual health care professions act (BIG)

- Protects patients from unprofessional treatment
- Authorizes nurses to carry out certain activities under order from authorized professionals
- Nursing practice is regulated by law



Karin Feicke MANP



---

---

---

---

---

---

---

---

## Career possibility for first level nurses: NP

### Master of Advanced Nursing Practice

- Since 1997
- 2 years post HBO course

### NP operates in the field between cure and care

- Qualified to also treat the patient
- Legally responsible for the treatment

Pioneer role in process of rearranging tasks in a clinic

Karin Feicke MANP



---

---

---

---

---

---

---

---

## Changes in the health care system



---

---

---

---

---

---

---

---

## Recent changes in the health care system

Shortage of health care professionals

Costs of the health care increasing

Competition in the health care sector

- Patient's safety
- Patient's satisfaction
- Quality management systems

Karin Feicke MANP



---

---

---

---


---

---

---

---

## New approaches to organize health care teams



Karin Feicke MANP



---

---

---

---

---

---

---

---

## Nursing in fertility clinics

Many similarities

Many differences

- Design and set up
- Local regulations
- Local management decisions
- Diversity of nurses
- Diversity of other health care professionals

Karin Feicke MANP



---

---

---

---

---

---

---

---

Example: UMCG fertility clinic



---

---

---

---

---

---

---

---

UMCG – Numbers of cycles in 2008

IVF	490
ICSI	945
Cryo ET	128
IUI	421
Insemination / donorsemen	212

Karin Feicke MANP



---

---

---

---

---

---

---

---

3/4

UMCG – Medical staff

Profession	Individuals	Time
Gynaecologists	4	3.8
IVF doctors	4	3.6
Fertility Nurses	3	2.3
Nurse practitioners	2	1.8
Embryologists	3	2.6
Lab technicians	12	9.1

Karin Feicke MANP



---

---

---

---

---

---

---

---

## Nurses tasks and interventions



---

---

---

---

---

---

---

---

## UMCG – Fertility nurses

### Competences

- To assess, carry out and evaluate the nursing care during and after the IVF treatment
- Carry out and assist with procedures ordered by the doctor
- Administration
- Participate in working with a quality management system

Karin Feicke MANP



---

---

---

---

---

---

---

---

## Specific nursing care in a fertility center

- Informing about the IVF procedure
- Advising and counselling before, during and after the treatment
- Create empathic relationship to let them talk openly
- Help the couple to cope with differences in communication and the emotional impact
- Ask other professionals in consult if needed

Leerboek O&G verpleegkunde, Voortplantingsgeneeskunde, De Haan, Spelt, Elsevier 2006

Karin Feicke MANP



---

---

---

---

---

---

---

---

## Nursing care interventions (1)

### Intake for starters in group sessions

- Logistic in the clinic and laboratory works
- Emotional impact
- Medication, side effects and physical discomfort
- Individual schedules and accessibility
- Chances of the different sorts of treatments
- Time and intimacy, free to ask
- Injection classes

Karin Feicke MANP



---

---

---

---

---

---

---

---

## Nursing care interventions (2)

### Daily consulting hour by telephone

- For reassurance and advice
- Nurses inform about patients history and complaints
- Supervision if needed



Karin Feicke MANP



---

---

---

---

---

---

---

---

## Focus: Health education



---

---

---

---

---

---

---

---

## Health education (1)

Patients are partners with rights and responsibilities

Teach the patient what they can do themselves

Health education can make the patient feel better and more in control



Karin Feicke MANP



---

---

---

---

---

---

---

---

## Health education (2)

Promote people's health and a healthy lifestyle

- Healthy body weight and healthy diet
- Regular physical exercises
- Reduction alcohol consumption and smoking
- Intake of folic acid supplementation

Karin Feicke MANP



---

---

---

---

---

---

---

---

## Care for emotional well being – why?

Make the patient feel good

- about the whole package of care from the team
- not only about an achieved pregnancy

It's not only the numbers of given life births but the grading of the psychological wellbeing

Not only the cure but also the care we offer

Aftercare

Karin Feicke MANP



---

---

---

---

---

---

---

---

### Care for emotional well being – how?

Patients want to be reassured – Explain to them

Keep it simple and clear

- Offer written information, booklets, cd roms
- Use visible tools, sheets, tables, figures and numbers
- Use no medical abbreviations or terms

Check and evaluate if the patient understands

Karin Feicke MANP



---

---

---

---

---

---

---

---

### Care for emotional well being: how?

Observe the capability of the couple in handling their fertility problems

Try to identify and meet the patient's needs

Listen to them

Notice and detect problems

Speak for their needs and call in other professionals

Karin Feicke MANP



---

---

---

---

---

---

---

---

### Challenges in Nursing



---

---

---

---

---

---

---

---

**For us who nurse, our Nursing is a thing, which, unless we are making progress every year, every month, every day... we are going back.**

Florence Nightingale, 1872

Karin Feicke MANP



---

---

---

---

---

---

---

---

### Challenge 1

**Get ready for lifelong learning!**

- Reflect to your actions and thoughts
- Be open to change
- Effective and efficient



Karin Feicke MANP



---

---

---

---

---

---

---

---

### Challenge 2

**Participate in rearranging tasks**

- Think and be constructive and pro-active
- Where possible and sensible
- In cooperation with other health workers



Karin Feicke MANP



---

---

---

---

---

---

---

---



## Examples

Coordinating and planning the care from the start to the end

Participate and setting up (nursing) research

Individual consultations with nurses

Offering good aftercare



Karin Feicke MANP



---

---

---

---

---

---

---

---

## Take home message

Nurses have crucial role and position

Many opportunities

Do think ambitious!

Karin Feicke MANP



---

---

---

---

---

---

---

---

## References

[www.CBS.org](http://www.CBS.org)

[www.WHO.org](http://www.WHO.org)

'Tien jaar resultaten van IVF in NL, 1996-2005',  
J.A.M. Kremer et al, NTG, 2008

Leerboek O&G verpleegkunde, voortplantingsgeneeskunde,  
De Haan, Spelt, Elsevier 2006

Karin Feicke MANP



---

---

---

---

---

---

---

---



**The impact of metabolic fitness on physically inactive obese women with a body mass index (BMI) over 30 and polycystic ovary syndrome (PCOS)**  
Master project in Master of Sport, Physical Activity and Wellness  
Head Nurse Birgitte Raaschou Holbæk Fertility Clinic, Holbæk, Denmark

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

The purpose of the present study is.

- To investigate whether moderate aerobic training as the only intervention can be used as treatment for physically inactive obese (BMI>30) women with PCOS in order to relieve the endocrine and metabolic disorder.
- And how we can implement recommendations of daily physical activity for inactive obese (BMI>30) women with PCOS in the preconception clinic.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

## Agenda

### ■ PCOS

”The hidden women's disease”.

- Obesity development in Denmark.
- PCOS and insulin resistance.
- 12-week intervention study.
- Metabolic fitness/training.
- Results of the pilot project.
- Implementation in Holbæk Fertility Clinic.
- Conclusion.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

## PCOS – definition.

2 out of 3 criteria required.

- Oligo/amenorrhea.
- Hyperandrogenism.


Clinical and/or biochemical

- Polycystic ovary.

At least 12 follicles (2-9 mm) in one level and/or ovarian volume >10 cm<sup>3</sup>.

- Exclusion of other reason.

Rotterdam consensus 2003 ESHRE /ASRM



Brigitte Raaschou June 2009

---

---

---

---

---

---

---

---

## PCOS - presence, cause and symptoms

- PCOS affects 5-10% women in the developed world.
- It is the most common endocrine disorder among women of reproductive age.
- PCOS can be hereditary or may develop because of obesity and physical inactivity.
- The instances of metabolic consequences increases in relation to overweight (40 to 60% are obese): insulin resistance, glucose intolerance, elevated cholesterol and increased risk of cardio vascular diseases.
- Insulin resistance occurs in up to 75% of these cases.

Norman R et al; Polycystic ovary syndrome. The Lancet Vol.370 august 25 2007.  
Norman R et al; Polycystic ovary syndrome.MJA2004;180(3).

Brigitte Raaschou June 2009

---

---

---

---

---

---

---

---

## PCOS – objective and subjective symptoms.

- Objective symptoms.

Acne, unwanted hair growth, thinning hair in the forehead, abdominal obesity and increased waist/hip ratio. (apple shape)

Norman R et al; Polycystic ovary syndrome. The Lancet Vol. 370, August 25, 2007

- Subjective symptoms.

Fatigue, head ache, hot flashes, "sugar-addiction" lack of satiety satiety, sleep problems and mood swings with an increased risk of developing a depression.

www.pcoinfo.dk; Udengaard, H; Hvad er Polycystisk ovariesyndrom? 2007.

Brigitte Raaschou June 2009

---

---

---

---

---

---

---

---

## Agenda.

- PCOS "The hidden women's disease".
- Obesity development in Denmark.
- PCOS and insulin resistance.
- 12-week intervention study.
- Metabolic fitness/training.
- Results of the pilot project.
- Implementation in Holbæk Fertility Clinic.
- Conclusion.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---


---

## Overweight – an increasing problem in modern society.

- Overweight: BMI>25-29.99  
30 – 40% in Denmark.
- Obesity: BMI≥30  
10-13% in Denmark.
- Region Sealand 30% higher than the national average  
30-40% with a BMI>25.
- 1 out of 7 are obese in Region Sealand.

The tables show the development of the share (%) of very overweight adult women from 1997 to 2005 in different ages and the distribution in Denmark.

[http://www.sfoikesundhed.dk/Ugens%20ta%20for%20foikesundhed/Ugens%20ta%2037\\_2006.aspx](http://www.sfoikesundhed.dk/Ugens%20ta%20for%20foikesundhed/Ugens%20ta%2037_2006.aspx)



Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

## Overweight – an increasing problem in modern society.

- In 2004 31.7% of the pregnant women were overweight in Denmark.
- In the 1st half of 2008 the number has risen to 33.7%.

<http://www.sst.dk/default.aspx?path=%7B47566AC9-C83E-40C9-A63C-0E59F196CEE7%7D&print=1>

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

## Overweight and pregnancy complications after IVF/ICSI.

	DM OR (95%)	Hypertension OR (95%)	Pre-eclampsia OR (95%)
BMI< 25	1	1	1
BMI 25-29.9	3.4 (1.7-6.8)	1.9 (0.97-3.7)	1.7 (1.2-2.4)
BMI>30	15.3 (8.2-28.6)	4.8 (2.3-9.9)	2.8 (2.0-4.1)

Rode et al., Obstet Gynecol; 2005 105

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

## Agenda.

- PCOS "The hidden women's disease".
- Obesity development in Denmark.
- **PCOS and insulin resistance.**
- 12-week intervention study.
- Metabolic fitness/training.
- Results of the pilot project.
- Implementation in Holbæk Fertility Clinic.
- Conclusion.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

## PCOS and insulin resistance.

- " Polycystic ovary syndrome is not only the major cause of ovulatory dysfunction and of hirsutism but is also associated with insulin resistance and is now recognised as an important risk factor for type 2 Diabetes.

Franks Stephen, How good are we at diagnosing polycystic ovary syndrome? Clinical Endocrinology Vol. 67 Dec. 2007.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

## Weight loss.

- A weight reduction of between 5 and 10% of the initial weight has shown that it can reestablish spontaneous ovulation and increase the insulin sensitivity in 71% of overweight anovular women.

Clark A M et al; Weight loss in obese infertile women result in improvement in reproductive outcome for all forms of fertility treatment. Hum. Repr.vol.13 1998  
Norman R et al; Polycystic ovary syndrome. The Lancet Vol.370 august 25, 2007.  
Svendsen PF, et al; Polycystisk ovariesyndrom. Ugeskrift for læger; 167, 2005

- Such a weight loss is the same as a reduction of visceral fat of about 30% which can explain why even a limited weight loss can enhance metabolic and reproductive functions

Balen A et al; Impact of Obesity on female reproductive health: British Fertility Society, Policy and Practice Guidelines. Human Fertility,2007;1-121 First article

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

## Agenda.

- PCOS "The hidden women's disease".
- Obesity development in Denmark.
- PCOS and insulin resistance.
- 12-week intervention study.
- Metabolic fitness/training.
- Results of the pilot project.
- Implementation in Holbæk Fertility Clinic.
- Conclusion.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

12-week intervention study for physically inactive obese women with a body mass index (BMI) over 30 and polycystic ovary syndrome (PCOS).

### Hypothesis:

Increased physical activity increases the insulin sensitivit in physically inactive women with BMI over 30 and PCOS.

- Increased insulin sensitivity can help lower and/or normalise the androgen level.
- Increased physical activity will:
  - Reduce insulin resistance.
  - Have a positive influence of lipid status with ↓ total cholesterol ↓ LDL and ↑ HDL.
  - Reduce abdominal and visceral fat with a decreased waistline.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

### 12-week intervention study.

#### Inclusion criteria:

- Age 25-35 (mean 29.8 (25-34))
- BMI  $\geq$  30 (mean 37.6 (31.4-47.8))
- VO2 max  $<$ 25 (16-25.1)
- P-FSH  $<$  7,5IU/L (4.8 (3-6))
- PCOS.

#### Exclusion criteria:

- Pregnancy.
- Type-1 and Type-2 Diabetes.
- Medical treatment, birth control pills.
- Competitive illnesses or handicaps.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

### 12-week intervention study.

#### The training intervention.

- 2 weekly supervised training of 1 hours duration.
- 30 min daily physical activity with moderate intensity. (slightly out of breath)
- 10,000 paces daily.
- Training intensity: Light to moderate intensity. (slightly out of breath, pulse 120-140)

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

### 12-week intervention study.

- Home training: bicycling, walking, dancing, ball games, swimming and gardening.

The amount of training was documented in the training diary and the strain was registered via a pulse watch.

- Supervised training: Nordic Walking, workout, aerobic, ball exercises, weight-lifting, elastics, circle training and pair exercises.

The strain of the training was registered every 10 minutes via a pulse watch.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

## 12-week intervention study.



Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

## Metabolic fitness/training. (metabolic condition)

- The capability of the cells to absorb and metabolize nutrients i.e. the mitochondria of the cells. "energy stations" are more active and produce more enzymes. (better absorption of sugar)

Sundhedsstyrelsen - Center for forebyggelse FYSISK AKTIVITET-håndbog om forebyggelse og behandling 2003

- The increased activity can take place regardless of improved physical fitness.

Kiens.B. et al. Fysisk inaktivitet- konsekvenser og sammenhænge Motions- og ernæringsrådet 2007

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

## Agenda.

- PCOS "The hidden women's disease".
- Obesity development in Denmark.
- PCOS and insulin resistance.
- 12-week intervention study.
- Metabolic fitness/training.
- Results of the pilot project.
- Implementation in Holbæk Fertility Clinic.
- Conclusion.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---



**Results:**  
Amount and intensity of the training.

5 physically inactive obese women with PCOS went through:

- On average 22 out of 24 available supervised training session of the duration of 1 hour.
- On average 66 (60-71) out of 84 available home training sessions incl. supervised training sessions.
- Walked on average 8140 paces daily. (6172-10788)
- Trained with an average pulse of 130. (126-137)

Birgitte Raaschou June 2009

---

---

---

---

---

---


---

---

---

---

**Results:**  
Number of daily paces.



- The number of average paces daily was 8140 (6172-10788).
- The recommended was 10,000 paces/daily.

Birgitte Raaschou June 2009

---

---

---

---

---

---


---

---

---

---

**Results:**  
Waistline and BMI.



- Mean reduction in waistline of 4.1 (0-8.5 cm)
- Mean reduction in BMI of - 0.2 (+ 0.7- -1.1 cm)

Birgitte Raaschou June 2009

---

---

---

---

---

---


---

---

---

---

Results:  
 ↑ VO2- max and training intensity (pulse).



- VO2-max 20.3 (16-25.1) ml/kg/min to 26.3 (18.8-36.3) ml/kg/min. Increase in i % 30 (18-45).
- Training intensity (pulse).
  - Structured training 134. (130-143)
  - Unsupervised home training (30 min/day) 127.(122-132)

Birgitte Raaschou June 2009

---

---

---

---

---

---


---

---

---

---

Results:  
 ↓ S-Insulin and ↑ SHGB.



Birgitte Raaschou June 2009

---

---

---

---

---

---


---

---

---

---

Results:  
 Total cholesterol, P-HDL and P-LDL.



Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

---

---

Conclusion: Metabolic fitness effect on physically inactive obese women with a BMI over (30) and PCOS.

- S-Insulin ↓ SHGB↑.  
SHGB binds the male hormones → helps to normalize the hormone balance → increase pregnancy chances.
- Modification of body composition with reduction in waistline → reduces the risk of developing metabolic consequences.
- VO2-max improved by 18 to 45% → decreased risk of developing cardiovascular disorders.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

Agenda.

- PCOS "The hidden women's disease".
- Obesity development in Denmark.
- PCOS and insulin resistance.
- 12-week intervention study.
- Metabolic fitness/training.
- Results of the pilot project.
- Implementation in Holbæk Fertility Clinic.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

Implementation of preconception care in Holbæk Fertility Clinic.

- Preconception care is the first treatment offer for obese and physically inactive women with a BMI>30 and PCOS women with a BMI>27 and/or a waistline > 88 cm.
- Treatment offer:  
Guidance in life style changes in the form of exercise and change of diet.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

### How to implement preconception care in Holbæk Fertility Clinic.

- 1. Consultation with a fertility doctor in the clinic.
- If BMI>30 and PCOS women with a BMI>27 and/or a waistline > 88 cm.
- Preconception care programme establish.

Birgitte Raaschou June 2009

---

---

---

---


---

---

---

---

### How to implement preconception care in Holbæk Fertility Clinic.



Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

### Preconception care.

- Medical history based on a questionnaire
  - Investigate life style. (diet, exercise, work life, daily rhythm, private life)
  - What is the cause of the overweight? (e.g. PCOS, mental state, nature and nurture)
  - What are their previous experiences with weight loss? (good, bad)
  - Investigate resources. (e.g. personal/family relations)

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

## Preconception care.

Dialogue based on questionnaire.

- What are the consequences of obesity for you and your fertility?
- How do you loose weight?
  - Diet. ("the 8 dietary")
  - Exercise. ("30 min. daily and 1 hour two times a week")
  - Other. (Metformin)
- Where to start (partial aim and plan)?
  - INDIVIDUAL GOALS.
  - Clear roles. (responsibility)
  - Plan for future contact. (via telephone and conversations)
- Following conversations
  - Stress that this is a change of life where the low insulin sensitivity is the main focus.
  - How close are we to the goal – what needs to be adjusted?

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

Thanks.

- Holbæk Fertility Clinic.
- Merck Serono.

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

Thank you for your time!

Birgitte Raaschou June 2009

---

---

---

---

---

---

---

---

## Ultrasound: How it works

**Ellen vd Vorst**  
Nurse reproductive medicine  
UMCN St Radboud  
Nijmegen, the Netherlands

---

---

---

---

---

---

---

---

## Objectives

- Basic anatomy
- Physiological changes during the menstrual cycle
- Follow a IVF cycle/image recognition
- Discuss a few pathologies

---

---

---


---

---

---

---

---



---

---

---

---

---

---

---



---

UMC St Radboud

## Types of transducers

which we use in gynecology

- Vaginal probe
- Abdominal probe

---

---

---

---

---

---


---

---

UMC St Radboud

## Trans vaginal ultrasound

- High resolution
- Loses detail on distance
- Empty bladder




---

---

---

---

---

---

---

---

UMC St Radboud

## Ultrasound terms

- Echogenic: an image that reflects most ultrasound waves; appears white or bright; hyperechoic
- Anechoic: an image that transmits most ultrasound waves; appears dark or black; hypoechoic
- Isoechoic: an image that both reflects and transmits ultrasound waves; appears grey; homogenous

---

---

---

---

---

---

---

---




---

---

---

---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---



### Endometrial

- Composed of basal and functional layer
- Functional layer responds to hormonal changes

---

---

---

---

---


---

---

---

### First ultrasound before starting with recombinant FSH Uterus

Thin endometrial



---

---

---

---

---

---

---

---

### First ultrasound before starting with recombinant FSH



---

---

---

---

---

---

---

---

UMC St Radboud

## Endometrium proliferative Phase

- Developing follicle → Estrogen goes up  
 → proliferation of the endometrial (8-16 mm)
- Triple layer

---

---

---

---

---

---

---

---

UMC St Radboud

## Second ultrasound

- After stimulation with recombinant FSH
- Ultrasound on day 9-10
- Measuring the endometrial
- Measuring the follicles

Make a new appointment or schedule a follicle puncture

---

---

---

---

---

---

---

---

UMC St Radboud

## Second ultrasound after stimulation with recombinant FSH

Thick endometrial after stimulation

---

---

---

---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---

---


---

---

UMC St Radboud

### Trans abdominal ultrasound

- Low resolution
- Lose little sharpness in depth
- Full bladder



---

---

---

---

---


---

---

---

UMC St Radboud

### Trans abdominal ultrasound during embryo transfer



---

---

---

---

---

---

---

---

UMC St Radboud

# PATIENT EDUCATION AND INVOLVEMENT USING THE INTERNET

Wouter Tuil, PhD  
Radboud University Medical Centre Nijmegen

ESHRE Annual Meeting 2009, Amsterdam

---

---

---

---

---

---

---

---

UMC St Radboud

## Overview

- Introduction
- Patient education
- Patient involvement
- Personalisation
- Virtual IVF clinic
- Getting started
- Conclusion

---

---

---

---

---

---

---

---

UMC St Radboud

## Introduction

- Internet is an healthcare revolution
- Patients demand online tools
- Clinic's general website
  - Limited functionality
  - Limited quality
- Great opportunities
  - Counselling
  - Interaction

---

---

---

---

---

---

---

---

UMC St Radboud

## PATIENT EDUCATION

---

---

---

---

---

---

---

---

UMC St Radboud

### Patient education

- Generic information
  - Disease / illness
  - Examinations
  - Treatment protocols
  - Scientific research programs
  - Clinic's staff
  - Contact information
  - Frequently Asked Questions (FAQ)
- Personal Health Status
  - Diagnostics tests
  - Prognosis
  - Treatment outcome

---

---

---

---

---

---

---

---

UMC St Radboud

### Patient education

- Skills
  - Instructions
  - Coping
  - Assertiveness
  - Information management
  - Lifestyle management

---

---

---

---


---

---

---

---



UMC  St Radboud

## PATIENT INVOLVEMENT

---

---

---


---

---

---

---

---

UMC  St Radboud

### Patient involvement

- Shared Decision Making
  - Access to medical information
  - Decision support systems
- Record keeping
  - Data entry
    - Intake / evaluation forms
    - Order entry
    - Telecare / home monitoring
  - Data corrections
- Process improvement
  - Guideline adherence
  - Suggestion box

---

---

---


---

---

---

---

---

UMC  St Radboud

### Patient involvement

- Online peer-to-peer support
  - Exchange experiences
  - Advice
    - Coping
    - Lifestyle
    - Social support
    - Work

---

---

---

---

---

---

---

---

UMC St Radboud

**PERSONALISATION**

---

---

---

---

---

---

---

---

UMC St Radboud

**Personalisation**

- Personalised information website
- Personalised health record
- Personalised prognosis
- Personalised protocol

---

---

---

---

---

---

---

---

UMC St Radboud

**VIRTUAL IVF CLINIC**

---

---

---

---

---

---

---

---

UMC St Radboud

### Virtual IVF Clinic

- Content:
  - Generic information
    - About the treatment
    - About the clinic
  - Personal information
    - Access to the medical record
  - Communication
    - Bulletin board
    - Chatroom

---

---

---

---

---

---

---

---

---

---

UMC St Radboud

### Virtual IVF Clinic

---

---

---

---

---

---

---

---

---

---

UMC St Radboud

### Virtual IVF Clinic

- Results

---

---

---

---

---

---

---

---

---

---

**Virtual IVF Clinic – Usefulness**

Generic Information	Useful	Not Useful
1. Frequently Asked Question	88%	12%
2. Information about the clinic	67%	33%
3. Information about the treatment	63%	37%
4. Personal experieces	50%	50%
5. Extrenal links	50%	50%
6. Recommended literature	33%	67%
7. Video fragments	31%	69%

Tuil et al, Human Reproduction 2006

---

---

---

---

---

---

---

---

---

---

---

---

**Virtual IVF Clinic – Usefulness**

Patiënt specific information	Useful	Not Useful
1. Personal Health Record	96%	4%
2. Day planner	92%	8%
3. Embryonic photographs	79%	21%
4. Personalised prognosis	78%	22%
5. Correspondence	49%	51%

Communication	Useful	Not Useful
1. E-mail	77%	23%
2. Bulletinboard	75%	25%
3. Chatroom	58%	43%

Tuil et al, Human Reproduction 2006

---

---

---

---

---

---

---

---


---

---

---

---

**Virtual IVF Clinic – Timeframe**



Tuil et al, Human Reproduction 2006

---

---

---

---

---

---

---

---

---

---

---

---

UMC St Radboud

**Virtual IVF Clinic – Styles**

- 3 Styles of usage:
  1. Individual information style (33,2%)
  2. Generic information style (29,0%)
  3. Communication style (37,8%)
- Correlations:
  - Style 1 ↔ paid employment (-)
  - Style 1 ↔ emotion coping (-)
  - Style 3 ↔ paid employment (+)
  - Style 3 ↔ anxiety (+)

Tuil et al, Human Reproduction 2008

---

---

---

---

---

---

---

---

UMC St Radboud

**GETTING STARTED**

---

---

---

---

---

---

---

---

UMC St Radboud

**Getting started**

- ① Listen !!!
  - Focus group / interviews / questionnaires
- ② Set attainable goals
  - Limited number of goals
  - Realistic ambitions
  - Solid business case
  - Avoid extra workload
- ③ Measure
  - Don't believe the hype
- ④ Take action
  - Improve your service level

---

---

---

---

---

---

---

---

UMC St Radboud

**CONCLUSION**

---

---

---

---

---

---

---

---

UMC St Radboud

**Conclusion**

- The internet can help in:
  - Educate patients
  - Involve patients
- Improves
  - Outcome
  - Process
- Beneficial results are in reach
- Best practices are rare

---

---

---

---

---

---

---

---

## Vitrification of human embryos: Will it replace slow controlled-rate freezing?

Maureen Wood PhD  
Department of Obstetrics and Gynaecology  
University of Aberdeen



---

---

---

---

---

---

---

---

## Disclosure

The speaker has no commercial relationships  
or other conflicts of interest to declare

---

---

---

---

---

---

---

---

## Learning objectives

- To understand the differences between freezing and vitrification
- To evaluate the evidence that vitrification should replace freezing, including:
  - Practical aspects
  - Outcome (embryo survival, pregnancy and livebirths)
  - Risks for children born from vitrified and frozen embryos

---

---

---

---

---

---

---

---

## Introduction

- Embryo storage vital in assisted conception
- Increases cumulative pregnancy rates
- Demand growing
  - Improved embryo quality
  - Introduction of eSET
  - PGD/PGS
- Fertility conservation

---

---

---

---

---

---

---

---

## Dilemma

- Slow controlled freezing
  - Outcome variable
  - Embryo viability reduced?
- Should vitrification replace freezing?

---

---

---

---

---

---

---

---

## Learning objectives

- To understand the differences between freezing and vitrification
- To evaluate the evidence that vitrification should replace freezing, including:
  - Practical aspects
  - Outcome (embryo survival, pregnancy and live births)
  - Risks for children born from vitrified and frozen embryos

---

---

---

---

---

---

---

---



## Outline

- History of embryo storage
- Principles of freezing and vitrification
- Compare:
  - Practical aspects
  - Outcome
  - Risks

---

---

---

---

---

---

---

---

## Chronology of embryo freezing

1972 Mouse embryos frozen  
1984 Human 8-cell embryos: DMSO  
1984 Human blastocysts: glycerol  
1984 Mouse embryos: PrOH  
1985 Human embryos: PrOH

---

---

---

---

---

---

---

---

## Chronology of embryo vitrification

1985 Mouse embryos vitrified  
1987 Live mice from vitrified embryos  
*Less toxic solutions developed*  
1994 Vitrification = freezing in mouse

---

---

---

---

---

---

---

---

### Vitrification vs Freezing Mouse 8-cell embryos

	Vitrification	Freezing
No embryos	206	157
% Survived	97	99
% Implanted	76	85
% Foetuses/Live Births	65	77
Overall survival (%)	63	76

Rall & Wood, 1994

---

---

---

---

---

---

---

---

### Chronology of embryo vitrification

- 1985 Mouse embryos vitrified
- 1987 Live mice from vitrified embryos  
*Less toxic solutions developed*
- 1994 Vitrification = freezing in mouse
- 1998 Birth from vitrified human 8-cell
- 1999 Birth from vitrified blastocyst

---

---

---

---

---

---

---

---

### Principles of freezing and vitrification

---

---

---

---

---

---

---

---

Cryopreservation

Freezing: ice

---

---

---

---

---

---

---

---

Cryopreservation

Freezing: ice  
Vitrification: glass

---

---

---

---

---

---

---

---

Cryopreservation

Freezing: ice  
Vitrification: glass  
AIM  
Prevent internal freezing  
Remove intracellular water

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

## Recent breakthrough in vitrification

- Cooling in ultra-small volumes
  - Increases cooling rate
- Decreased concentration of cryoprotectant
  - Minimises toxicity

---

---

---

---

---

---

---

---

## Vitrification containers

These include:

- Copper grid
- Metal loop
- Finely pulled straw (OPS)
- CryoTop
- CryoTip
- CryoLeaf
- HSV straw

---

---

---

---

---

---

---

---

Evidence that vitrification should replace freezing?

---

---

---

---

---

---

---

---

## Vitrification vs Freezing

- Quicker
- Simpler
- Less costly
- Better outcome
- An open and shut case?

---

---

---

---

---

---

---

---

## How successful is vitrification in practice?

- Practical advantages?
- Robust?
- Improved survival?
- Live births per embryo?
- Safe?

---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---


---

---

---

---






---



---



---



---



---




---



---



---




---



---



---



---



---




---



---



---




---



---



---



---



---



---



---



---

## Incident

- Supplying clinic vitrifies
- Receiving clinic freezes
- No embryos survived
- Transport temperature?
- Error in warming?

---

---

---

---

---

---

---

## Safeguards

- Controlled transport
- *Precise* protocol in advance
- Correct warming solutions
- Practise warming procedure

---

---

---

---

---

---

---

## How successful is vitrification in practice?

- Practical advantages?
- Robust?
- Improved survival?
- Live births per embryo?
- Safe?

---

---

---

---

---

---

---

## Freezing vs Vitrification<sup>†</sup>

	Frozen	Vitrified
No. embryos warmed	232	234
% Survived	89	95*
% Blastocysts	50	60*
Overall survival	44	57*

Metabolism significantly reduced after freezing

<sup>†</sup>Data from donated supernumerary day 3 embryos (Balaban *et al* 2005)

---

---

---

---

---

---

---

---

## Survival of biopsied embryos

Method	Embryos (n)	% Survived	% Blastocyst
Slow freeze	Control (53)	85	20
Slow freeze	Biopsied (52)	16	2
Modified freeze	Biopsied (52)	75	23
Modified thaw	Biopsied (50)	76	14
Vitrification	Biopsied (49)	94	18

Zheng *et al* 2005

---

---

---

---

---

---

---

---

## Vitrification vs Freezing in clinical practice

### Better outcome?

- embryo survival
- implantation
- pregnancy
- live birth

---

---

---

---

---

---

---

---

## Vitrification vs Freezing

	Frozen	Vitrified	No. reports vitrified> frozen
% Survival	60-92	90-100	4/5
% Pregnancy per ET	17-51	27-53	2/5

Kuwayama *et al* 2005; Raju *et al* 2005; Stehlik *et al* 2005; Liebermann & Tucker 2006

---

---

---

---

---

---

---

---

## Freezing vs vitrification Embryo survival

	% Embryos surviving (n)				
	4-cell	6-8-cell	Blastocyst		
Frozen	91 (942)	60 (120)	84 (156)	86 (147)	92 (570)
Vitrified	98* (897)	95* (127)	90* (6328)	100* (77)	97 (547)

Kuwayama *et al* 2005; Raju *et al* 2005; Stehlik *et al* 2005; Liebermann & Tucker 2006

---

---

---

---

---

---

---

---

## Freezing vs vitrification Pregnancy rates

	% Pregnancy per ET (no of ET)				
	4-cell	6-8-cell	Blastocyst		
Frozen	32 (536)	17 (23)	51 (98)	18 (51)	46 (254)
Vitrified	27 (504)	35* (40)	53 (4745)	43* (35)	43 (254)

Kuwayama *et al* 2005; Raju *et al* 2005; Stehlik *et al* 2005; Liebermann & Tucker 2006

---

---

---

---

---

---

---

---

## Outcome of freezing vs vitrification

- Lack of prospective randomisation
- Unequal/small samples
- Definition of survival
- Definition of pregnancy
- Lack of live birth data
- Inadequate freezing protocols

---

---

---

---

---

---

---

---

## Vitrification vs freezing

Does the method of cryopreservation carry any risk for the children conceived from the embryos?

---

---

---

---

---

---

---

---

## Risks for the children?

### Freezing

- >350,000 children
- Follow-up studies
- Long term effects?

### Vitrification

- >3000 children
- No follow-up
- Long term effects?

---

---

---

---

---

---

---

---

# Conclusions

- Vitrification very promising
- Before replacing freezing:
  - Prospective randomised comparisons
  - Assess “robustness” in various clinics
  - Live birth data
  - Safety during storage
  - Examine freezing protocols

---

---

---

---

---

---

---

---

## REFERENCES

- Balaban B, Urman B, Ata B, Isiklar A, Larman MG, Hamilton R and Gardner DK. (2008) A randomized controlled study of human Day 3 embryo cryopreservation by slow freezing or vitrification: vitrification is associated with higher survival, metabolism and blastocyst formation. *Human Reproduction*, 23:1976-1982
- Choi DH, Chung HM, Lim JM, Ko JJ, Yoon TK and Cha KY. (2000) Pregnancy and delivery of healthy infants developed from vitrified blastocysts in an IVF-ET program. *Fertility and Sterility*, 4:838-839
- Cohen J, Simons RF, Edwards RG, Fehilly CB and Fishel SB. (1985) Pregnancies following the frozen storage of expanding human blastocysts. *J. in vitro Fertilization and Embryo Transfer*, 2:59-64
- Kuwayama M, Vajta G, Ieda S and Kato O. (2005) Comparison of open and closed methods for vitrification of human embryos and the elimination of potential contamination. *Reproductive Biomedicine Online*, 11:608-614
- Lassalle B, Testart J and Renard J-P. (1985) Human embryo features that influence the success of cryopreservation with the use of 1,2 propanediol. *Fertility and Sterility*, 44:645-651
- Liebermann J and Tucker MJ. (2006) Comparison of vitrification and conventional cryopreservation of day 5 and day 6 blastocysts during clinical application. *Fertility and Sterility*, 86:20-26

---

---

---

---

---

---

---

---

- Mukaida T, Wada S, Takahashi K, Pedro PB, An TZ and Kasai M. (1998) Vitrification of human embryos based on the assessment of suitable conditions for 8-cell mouse embryos. *Human reproduction*, 13:2874-2879
- Rall WF and Fahy GM. (1985) Ice-free cryopreservation of mouse embryos at -196°C by vitrification. *Nature*, 313:573-575
- Rall WF, Wood MJ, Kirby C and Whittingham DG. (1987) Development of mouse embryos cryopreserved by vitrification. *J. Reprod. Fert.*, 80:499-504
- Rall WF and Wood MJ. (1994) High in vitro and in vivo survival of day 3 mouse embryos vitrified or frozen in a non-toxic solution of glycerol and albumin. *J Reprod Fert.*, 101:681-688
- Raju GAR, Haranth GB, Krishna KM, Prakash GJ and Madan K. (2005) Vitrification of human 8-cell embryos, a modified protocol for better pregnancy rates. *Reproductive Biomedicine Online*, 11:434-437
- Renard J-P and Babinet C. (1984) High survival of mouse embryos after rapid freezing and thawing inside plastic straws with 1-2 propanediol as cryoprotectant. *J. Exp. Zool.*, 230:443-448
- Stehlik E, Stehlik J, Katayama KP, Kuwayama M, Jambor V, Brohammer R and Kato O. (2005) Vitrification demonstrates significant improvement versus slow freezing of human blastocysts. *Reproductive Biomedicine Online*, 11:53-57
- Trounson A and Mohr L. (1983) Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. *Nature*, 305:707-709

---

---

---

---

---

---

---

---

- Whittingham DG, Leibo SP and Mazur P. (1972) Survival of mouse embryos frozen to -196°C and -269°C. *Science*, 178:411-414
- Zeilmaker G, Alberda A, van Gent I, Rykmans CMPM and Diendigh AC. (1984) Two pregnancies following transfer of intact frozen-thawed embryos. *Fertility and Sterility*, 42:293-296
- Zheng WT, Zhuang GL, Zhou CQ, Fang C, Ou JP, Zhang MF and Liang XY. (2005) Comparison of the survival of human biopsied embryos after cryopreservation with four different methods using non-transferable embryos. *Human reproduction*, 20:1615-1618

---

---

---

---

---

---

---

---



european society of human reproduction & embryology

## Vitrification

Working together – theory and practice

G. Bocken and I. De Croo



---

---

---

---

---

---

---

---

## Learning Objectives

- Basic principles of slow freezing
- Basic principles of vitrification
- Technical challenges of vitrification
- Short overview literature
- Closed vitrification procedure (by Geertrui Bocken)



---

---

---

---


---

---

---

---

## Introduction



---

---

---

---

---

---

---


---



## Freezing proces

extracellular ice formation : rise of osmolarity by

- 1) efflux of cell water  
→ cell shrinkage
- 2) formation of a solid phase in the cell  
→ intracellular ice



---

---

---

---

---


---

---

---

## Freezing proces : equilibrium cooling

- How ? :
- adding a cryoprotective agent (CPA) (Dimethylsulfoxide, glycerol, 1,2- propanediol, etc ...)
  - optimal slow cooling rate
  - inducing extracellular ice crystals (seeding)



---

---

---

---

---

---

---

---

## Cryoprotective agent (CPA)

A **cryoprotectant** is a substance that is used to protect **biological tissue from freezing damage** (damage due to ice formation).

Conventional **cryoprotectants** are glycols such as **ethylene glycol**, **propylene glycol** and **glycerol**. Ethylene glycol is commonly used as **automobile antifreeze** and **propylene glycol** has been used to reduce ice formation in ice cream.

**Dimethyl sulfoxide (DMSO)** is also regarded as a conventional cryoprotectant. Glycerol and DMSO have been used for decades by cryobiologists to reduce ice formation in sperm and embryos that are cold-preserved in liquid nitrogen.



---

---

---

---

---

---


---

---

### Examples of slow freezing protocols

#### Slow freezing protocol for embryos with DMSO

- Equilibration in 0.75 M and 1.5 M for 10 minutes each
- Transfer to a biological freezer



---

---

---

---

---

---


---

---

### Examples of slow freezing protocols

#### Slow freezing protocol for embryos with 1,2 PrOH

- Equilibration in 0 M and 1.5 M PrOH for 10 minutes for 10 minutes each
- Load straws in 1.5M + 0.1 M sucrose
- Transfer to a biological freezer



---

---

---

---

---

---

---

---

### Equilibrium cooling



---

---

---

---

---

---

---

---

## Vitrification

### Non-equilibrium cooling or vitrification

#### Definition

Vitrification is a process by which a liquid is solidified into a non-crystalline (glassy) phase by lowering rapidly the temperature below the 'glass transition' temperature and greatly increasing the viscosity



---

---

---

---

---


---

---

---

## Vitrification

- Dehydration before cooling
- Very high concentrations of CPA
- Very fast cooling ( $-25\,000\text{ }^{\circ}\text{C}/\text{min}$ ) to avoid damage by 'chilling'



---

---

---

---

---

---

---

---

## Example of vitrification protocol

- \* Equilibration for 10 minutes
- \* Exposure to vitrification medium for 20 sec in total (2 x 5 sec and 1x10 sec) and load the specimens to the carrier (max 90 sec)
- \* Plunge into liquid nitrogen

Total : +/- 12 minutes

But only 1 or 2 specimens at a time



---

---

---

---

---

---

---

---

## Vitrification



European Society of Human Reproduction & Embryology

---

---

---

---

---

---

---

---

## Vitrification

### Variables of vitrification

- Effect of cooling and warming rates  
Concentration of CPA low or near zero: cooling and warming rates  
> 1 000 000°C/min
- permeability of cells to water and CPA  
\*Glycerol> EG>DMSO>PG  
\*Oocytes<zygotes<embryos<blastocysts
- toxicity of CPA  
\*type and concentration of CPA  
PG>EG>DMSO>Glycerol  
\* temperature of exposure



European Society of Human Reproduction & Embryology

---

---

---

---

---

---

---

---

## Vitrification

### Vitrification and slow freezing : a comparison

Slow freezing	Vitrification
slow cooling (0.3°C/min)	very fast cooling ( 25 000°C/min)
low conc CPA (1.5M )	high conc CPA ( 5-7M)
ice crystallization	no ice crystallization
big volumes 250µl	very small volumes < 1µl
dehydration during cooling	dehydration before cooling
expensive equipment	expensive devices and vitrification solutions



European Society of Human Reproduction & Embryology

---

---

---

---

---

---

---

---

## Technical challenges of vitrification

- Small volumes : well trained embryologists
- High cooling rates : open systems  
direct contact with liquid nitrogen : cross contamination
- Search for an efficient closed carrier
- Concentration and type of CPA  
successful vitrification depends on 'sufficient' penetration of permeating CPA's and 'sufficient' dehydration by non-permeating CPA's
  - \*Permeability characteristics of cells to water and CPA
    - temperature and time dependency
    - variability amongst cells
- Risk of crystallization during storage or warming



---

---

---

---

---

---

---

---

## Vitrification

### Vitrification of :

- Oocytes*
- Embryos*
- Blastocysts*



---

---

---

---

---

---

---

---

## Vitrification



---

---

---

---

---

---

---

---

## Vitrification of oocytes

### Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method

Ann Clift, Ph.D.,<sup>1</sup> Marjorie K. Krawczuk, Ph.D.,<sup>2</sup> Anne Peters, Ph.D.,<sup>3</sup> Stephen Katz, M.D.,<sup>4</sup> Alexander Robinson, M.D.,<sup>5</sup> and David Brannan, M.D.<sup>6</sup>  
<sup>1</sup>City of Hope, <sup>2</sup>University of Wisconsin, <sup>3</sup>Rockefeller, <sup>4</sup>IVF Associates, <sup>5</sup>IVF Associates, <sup>6</sup>IVF Associates

**TABLE 3**  
Oocyte distribution, survival, and fertilization

	Vitrified	Fresh	P value
MI oocytes No. (%)	321 (67.2)	279 (55.7)	.262
MI oocytes No. (%)	16 (2.5)	11 (2.1)	.392
MI oocytes No. (%)	32 (5.3)	4 (3.7)	.874
Survival No. (%)	224 (51.9)	278	
No. of injected oocytes	224	278	
Normal fertilization No. (%)	171 (76.3)	180 (64.8)	.138
Abnormal fertilization No. (%)	8 (4.0)	12 (4.3)	.898
Degenerated oocytes No. (%)	25 (11.2)	8 (2.9)	.008

Note: MI=MI oocytes; MI=MI oocytes; MI=MI oocytes. MI=MI oocytes.




---

---

---

---

---

---

---

---

---

---

---

---

## Vitrification of oocytes

**TABLE 4**  
Clinical results

	Vitrified	Fresh	Mixed
No. of transfers	22	7	4
No. of embryos transferred (mean ± SD)	49 (2.7 ± 1.2)	2 (2 ± 0)	8 (2.1 ± 0.7)
Pregnancy rate per transfer	15 (22 (69.2)	1 (100)	2 (50)
Implantation rate (%) of eggs/embryos transferred	20 (48 (47.8)	3 (100)	24 (20)
Multiple pregnancies (rate %)	3 (15 (23.8)	1 (100)	0
Abortion rate	3 (15 (23.8)	0	0
Biological pregnancy rate	12 (54.5)	0	0
Clipping pregnancy rate	11 (22 (47.8)	1 (100)	2 (50)

Note: No. of embryos in parentheses are per centages.  
 Note: Clinical results of our cryopreservation. MI=MI oocytes.




---

---

---

---

---

---

---

---

---

---

---

---

## Vitrification




---

---

---

---

---

---

---

---

---

---

---

---

## Vitrification of cleavage stage embryos

### A randomised controlled study of human Day 3 embryos cryopreserved by slow freezing or vitrification: vitrification is associated with higher survival, metabolism and blastocyst formation

R. Bahabadi, R. J. Jones, S. H. Aziz, A. Ishimaru, M. D. Lammiman, R. Hamilton and D.R. Gardner<sup>1,2</sup>

Table II. Outcomes of vitrification and slow freezing

	Vitrification	Slow freezing	95% CI of difference	P-value
Cryosurvival (%)	222/214 (94.8)	206/232 (88.7)	+1% to +11%	0.02
Embryos with 100%	173/222 (77.9)	106/206 (51.4)	+18% to +35%	<0.01
Metabolic survival (%)	134/222 (60.3)	102/206 (49.5)	+1% to +2%	0.02
Blastocyst formation (%)	70/134 (52.2)	47/102 (42.1)	-27% to -22.9%	0.2
Hatching blastocysts (%)	47/134 (35.3)	27/102 (27.5)	-1.4% to +20.9%	0.09

CI, confidence interval.



european society of human reproduction & embryology

---

---

---

---

---

---

---

---

## Vitrification of cleavage stage embryos

Table III. Clinical outcomes of vitrified-normal embryo transfers

No. of women	52
No. of embryos vitrified (mean)	3.6 (4.3)
No. of embryos warmed (mean)	2.6 (1.5)
#Experimental (%)	222/340 (65.3)
No. of cycles with implant	166/222 (74.8)
Embryo survival (%)	146/222 (65.8)
No. of embryos transferred (mean)	1.98 (2.1)
No. of livebirths (%)	94/146 (64.4%)
#Clinical pregnancy rate (%)	36/71 (50.7%)
Fragility rate	29/76
Aborting pregnancy rate (%)	2.5/71 (4.2%)
Multiple pregnancy rate (%)	1.7/71 (2.4%) (1 triplet, 12 twinning)
Abortion (%)	0/36 (0%)
Deceased* (%)	9/77 (11.7%) (2 twins, 6 singletons)

\*Deceased until the time of writing the manuscript.



european society of human reproduction & embryology

---

---

---

---

---

---

---

---

## Vitrification



european society of human reproduction & embryology

---

---

---

---

---

---

---

---

## Vitrification of blastocysts

### Comparison of vitrification and conventional cryopreservation of day 5 and day 6 blastocysts during clinical application

Benigno Echiburuen, Ph.D.,\* and Michael J. Parker, Ph.D.,\*\*  
\*Medical Director of Assisted Conception, Baylor and Chicago Reproductive Specialists, Dallas, Chicago

TABLE 1

Retrospective data from the blastocyst cryopreservation program (Fertility Centers of Illinois, Chicago) where both vitrification (VIT) and conventional (CONV) technologies were applied from January 2004 to December 2005.

Technique	VIT	CONV
Patients' age (y)	34.2 ± 5.0	35.1 ± 4.7
No. of ovarian cycles	297	299
No. of ovaries	254	254
No. of blastocysts survived/thawed	427	570
No. of blastocysts survived (%)	528 (96.5)	525 (92.1)
No. of blastocysts transferred	523	518
Mean no. of blastocysts transferred	2.0	2.0
No. of implantations (%)	160 (30.8)	152 (29.6)
No. of positive pregnancy/thaw (%)	132 (51.4)	135 (52.1)
No. of positive pregnancy/FET (%)	132 (51.5)	135 (53.1)
No. of clinical pregnancy/thaw (%)	117 (45.5)	109 (42.1)
No. of clinical pregnancy/FET (%)	117 (45.1)	109 (42.9)
Ongoing pregnancies (%)	117 (88.6)	109 (79.6)
No. of livebirths	54	79

Note: P < .05 for every comparison. FET = frozen embryo transfer.

LifeSpan: Comparison of vitrification and conventional cryopreservation of blastocysts. Fertil Steril 2006.



European Society of Human Reproduction & Embryology

## Conclusion

Vitrification seems to be superior to slow freezing for oocytes, embryos and blastocysts regarding post-thaw survival

**BUT**

more prospective trials are needed to confirm this and to evaluate pregnancy outcomes and follow-up of the children



European Society of Human Reproduction & Embryology



European Society of Human Reproduction & Embryology

## Vitrification

Vit Kit™ – Freeze Technique



UNIVERSITAIR ZIEKENHUIS GENT



UNIVERSITAIR ZIEKENHUIS BRUSSEL



### Materials Required for Vitrification

- Stereomicroscope ( NIKON)
- Mini Incubator (K system)
- Stopwatch or Timer
- Liquid nitrogen (LN<sub>2</sub>) ( Air Liquide )
- Dewar Agil 3 ( Air Liquide)
- Sealer (Cryo Bio System)
- Flexipet<sup>®</sup> manipulation pipette (Cook)
  - Denuding pipette flexipet – K-FPIP-1300-10BS
- Stripper<sup>®</sup> (Cook)
  - Adjustable handle for all flexipet sizes – K-MPH-1000
- Petri-dish Falcon<sup>®</sup>
  - (Becton Dickinson) 351006 50 x 9 mm
- Eppendorf Research (20 -200 µl)
- Eppendorf biopur 200 µl



European Society of Human Reproduction & Embryology

---

---

---

---

---


---

---

---

### High Security Vitrification kit (Cryo Bio System)

- Composed of 3 parts:
  - A High Security ionomeric resin straw
  - A capillary tube with pre-formed gutter and colour-coded holder
  - A blue plastic insertion and removal device



- Sterilized by irradiation



European Society of Human Reproduction & Embryology

---

---

---

---


---

---

---

---

### High Security Vitrification kit (Cryo Bio System)



European Society of Human Reproduction & Embryology

---

---

---

---

---

---

---

---

## Vit Kit™ – Freeze (Irvine Scientific)

- Equilibration Solution (ES)
  - 7.5% v/v DMSO
  - 7.5 % v/v ethylene glycol
  - 20% Dextran Serum Supplement (DSS)
  - In M199-H
- Vitrification Solution (VS)
  - 15% v/v ethylene glycol
  - 15% v/v DMSO
  - 0.5 M sucrose
  - 20% Dextran Serum Supplement (DSS)
  - In M199-H




---

---

---

---


---

---

---

---

## Vitrification Protocol



- Prepare a Petri-dish with a droplet of 20  $\mu$ l HEPES buffered Culture Medium (H)
  - Hold at 37°C
- Transfer the specimen into the droplet
  - Hold the dish at room temperature
- Transfer the specimen in a droplet of 20  $\mu$ l ES solution
  - Expose to ES for 5 – 15 min
  - The specimen will shrink and then gradually return to its original size which indicates that the equilibration is complete.




---

---

---

---


---

---

---

---

## Vitrification Protocol



Load within 90 sec.



- Prepare four droplets of 20  $\mu$ l VS
- Rinse the specimen in the first droplet of VS (vs1) and transfer it quickly into the second (vs2) and third (vs3) one
- Finally, transfer the specimen to the fourth drop of VS (vs4)
- The specimen is now ready to be loaded on the straw and plunge into liquid nitrogen within 90 sec.




---

---

---

---

---

---

---

---

## High Security Vitrification kit (HSV) Loading



Fig. 1

- Deposit the specimen into the gutter a millimetre from the end. (fig.1)



Fig. 2

- Place the capillary rod on a handler into the straw and push until the rectangular portion of the handler comes in contact with the flared end of the straw (fig. 2)



Fig. 3

- Seal the open end using a SYMS sealer (fig. 3)



Fig. 4

- Quickly plunge the entire straw into the liquid nitrogen (fig. 4)



european society of human reproduction & embryology

---

---

---

---

---

---

---

---

---

---



european society of human reproduction & embryology

## Vitrification

Vit Kit™ – Thaw Technique



UNIVERSITAIR ZIEKENHUIS GENT



UNIVERSITAIR ZIEKENHUIS BRUSSEL

---

---

---

---

---

---

---

---

---

---

## Materials Required for Vitrification

- Stereomicroscope ( NIKON )
- Mini Incubator ( K System )
- Stopwatch or Timer
- Liquid nitrogen (LN<sub>2</sub>) ( Air Liquide )
- Dewar Agil 3 ( Air Liquide)
- Sharp scissors (sterile)
- Flexipet<sup>®</sup> manipulation pipette (Cook)
  - Denuding pipette flexipet – K-FPIP-1300-10BS
- Stripper<sup>®</sup> (Cook)
  - Adjustable handle for all flexipet sizes – K-MPH-1000
- Petri-dish Falcon<sup>®</sup>
  - (Becton Dickinson) 351006 50 x 9 mm
- Eppendorf Research (20 -200 µl)
- Eppendorf biopur 200 µl



european society of human reproduction & embryology

---

---

---

---

---

---

---

---

---

---

## Vit Kit™ – Thaw (Irvine Scientific)

- Thawing Solution (TS)
  - 1.0 M Sucrose
  - 20% DSS
  - In M199-H
- Dilution Solution (DS)
  - 0.5 M Sucrose
  - 20% DSS
  - In M199-H
- Washing Solution (WS)37
  - 20% DSS
  - In M199-H



European Society of Human Reproduction & Embryology

---

---

---

---

---

---

---

---

## Thaw protocol



Fig. 1



Fig. 2



Fig. 3

- Prepare a Petri-dish with 2 droplets of 20 µl TS
  - Hold at 37°C
- Lift the straw to expose the coloured rod. (fig.1)
  - Make sure that the end with the sample remains immersed in the liquid nitrogen.
- Cut the straw above the handling rod. (fig.2)
- Insert the short end of the removal device into the coloured handler and pull the capillary out of the straw (fig. 3)



European Society of Human Reproduction & Embryology

---

---

---

---


---

---

---

---

## Thaw protocol



- Put immediately the gutter into the first 20 µl TS droplet.
  - The specimen will be floating and bring it down.
  - Hold the Petri-dish at room temperature
- After 1 min. transfer the specimen in the other 20 µl TS droplet for another min.
- Prepare two DS droplets of 20 µl each
- Transfer the specimen to DS1 and DS2 drops for 2 min. each



European Society of Human Reproduction & Embryology

---

---

---

---


---

---

---

---

## Thaw protocol



- Prepare three WS droplets of 20  $\mu$ l each
- Transfer the specimen to WS1, WS2 and WS3 drops for 3 min. each
- After the last 3 min. In WS transfer the specimen in a culture system and evaluate the survival rate



---

---

---

---

---

---

---

---

# NOTES

# NOTES

# NOTES



# NOTES

# NOTES

# NOTES

# NOTES

# NOTES